Literature DB >> 10479386

Probing the immunological properties of the extracellular domains of the human beta(1)-adrenoceptor.

R Mobini1, Y Magnusson, G Wallukat, M Viguier, A Hjalmarson, J Hoebeke.   

Abstract

The human beta(1)-adrenoceptor is an immune target for autoantibodies with functional activity in cardiovascular diseases. Different epitopes on the extracellular domains of the receptor are involved. To study the immunological and pharmacological properties of these epitopes, rabbits were immunized with peptides corresponding to a large domain in the N-terminal part of the receptor and to its first and second extracellular loops. In contrast to the two other peptides, the first extracellular loop did not have immunogenic properties but acted as a hapten. Antibodies affinity-purified with the three synthetic peptides were able to significantly immunoprecipitate the solubilized receptor, confirming that they recognized the target receptor. While antibodies against the N-terminal domain did not inhibit the binding of a radiolabelled antagonist to the receptor, those against the first and second extracellular loop showed non-competitive inhibition. Similarly, only the two latter antibodies exerted a specific agonist-like effect on the receptor, as assessed on neonatal rat cardiomyocytes in culture. Our results are in accordance with those found for human anti-receptor autoantibodies with functional effects. We conclude that not all extracellular epitopes give rise to functional autoantibodies with potential physiopathological relevance in cardiac diseases with an autoimmune component. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479386     DOI: 10.1006/jaut.1999.0310

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  6 in total

Review 1.  Autoantibodies and cardiovascular dysfunction: cause or consequence?

Authors:  Yuji Nagatomo; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2014-12

2.  Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against β1-Adrenergic Receptors.

Authors:  Yuji Nagatomo; Dennis M McNamara; Jeffrey D Alexis; Leslie T Cooper; G William Dec; Daniel F Pauly; Richard Sheppard; Randall C Starling; W H Wilson Tang
Journal:  J Am Coll Cardiol       Date:  2017-02-28       Impact factor: 24.094

3.  Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy.

Authors:  Roland Jahns; Valérie Boivin; Lutz Hein; Sven Triebel; Christiane E Angermann; Georg Ertl; Martin J Lohse
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

4.  Atomic-level mapping of antibody epitopes on a GPCR.

Authors:  Cheryl Paes; Jada Ingalls; Karan Kampani; Chidananda Sulli; Esha Kakkar; Meredith Murray; Valery Kotelnikov; Tiffani A Greene; Joseph B Rucker; Benjamin J Doranz
Journal:  J Am Chem Soc       Date:  2009-05-27       Impact factor: 15.419

5.  Autoantibodies Specifically Against β1 Adrenergic Receptors and Adverse Clinical Outcome in Patients With Chronic Systolic Heart Failure in the β-Blocker Era: The Importance of Immunoglobulin G3 Subclass.

Authors:  Yuji Nagatomo; Daniel Li; Jennifer Kirsop; Alan Borowski; Akanksha Thakur; W H Wilson Tang
Journal:  J Card Fail       Date:  2016-03-17       Impact factor: 5.712

6.  MRI Assessment of Cardiomyopathy Induced by β1-Adrenoreceptor Autoantibodies and Protection Through β3-Adrenoreceptor Overexpression.

Authors:  Laetitia Vanhoutte; Céline Guilbaud; Ruben Martherus; Caroline Bouzin; Bernard Gallez; Chantal Dessy; Jean-Luc Balligand; Stéphane Moniotte; Olivier Feron
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.